The University of Southampton
University of Southampton Institutional Repository

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients
Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients

Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing and the shortcomings of current pathways to access testing. Approximately 15% of ovarian cancer patients have a germline BRCA1 or BRCA2 mutation which has substantial implications for their personal management and that of their relatives. Unfortunately, in most countries, routine implementation of BRCA testing for ovarian cancer patients has been inconsistent and largely unsuccessful. We developed a rapid, robust, mainstream genetic testing pathway in which testing is undertaken by the trained cancer team with cascade testing to relatives performed by the genetics team. 207 women with ovarian cancer were offered testing through the mainstream pathway. All accepted. 33 (16%) had a BRCA mutation. The result informed management of 79% (121/154) women with active disease. Patient and clinician feedback was very positive. The pathway offers a 4-fold reduction in time and 13-fold reduction in resource requirement compared to the conventional testing pathway. The mainstream genetic testing pathway we present is effective, efficient and patient-centred. It can deliver rapid, robust, large-scale, cost-effective genetic testing of BRCA1 and BRCA2 and may serve as an exemplar for other genes and other diseases.

Adult, Aged, Aged, 80 and over, BRCA1 Protein/genetics, BRCA2 Protein/genetics, Cost-Benefit Analysis, Female, Genetic Predisposition to Disease, Genetic Testing/economics, Humans, Middle Aged, Models, Organizational, Mutation, Neoplasms/diagnosis, Patient Satisfaction, Patient-Centered Care/economics, Program Development, Surveys and Questionnaires, Young Adult
2045-2322
29506
George, Angela
9d836dd2-b9fb-4a88-b0fc-b26044a2875d
Riddell, Daniel
a7a85f82-7f83-45b2-86b1-26b520c46e37
Seal, Sheila
d8090fdd-aa7a-40c4-a4e4-18a094e7671f
Talukdar, Sabrina
a04a95d0-9f03-45bd-a615-b654875df5b5
Mahamdallie, Shazia
7dde2c5e-39f7-4279-8eb5-2b5fde9bef9d
Ruark, Elise
c5c08cd3-5579-4525-85b4-a6f2cd5e9a86
Cloke, Victoria
5998e9f4-020a-4409-a8ee-c525ce3ca588
Slade, Ingrid
264e62f4-7c1e-4522-93f2-917de23e31d3
Kemp, Zoe
6d96320b-c976-4ea6-9b87-536deb9bb0c9
Gore, Martin
c38b4500-ccbd-4505-9c58-68c8b27b54f2
Strydom, Ann
e626e499-b5e6-4e23-b128-ddfe844cc97b
Banerjee, Susana
977eaccf-2029-4f7b-8577-4264c04c0550
Hanson, Helen
fe4a8065-8b0d-4b30-a658-cd433570c2ec
Rahman, Nazneen
d5eded76-0af9-4d72-8fea-84986bf49c51
George, Angela
9d836dd2-b9fb-4a88-b0fc-b26044a2875d
Riddell, Daniel
a7a85f82-7f83-45b2-86b1-26b520c46e37
Seal, Sheila
d8090fdd-aa7a-40c4-a4e4-18a094e7671f
Talukdar, Sabrina
a04a95d0-9f03-45bd-a615-b654875df5b5
Mahamdallie, Shazia
7dde2c5e-39f7-4279-8eb5-2b5fde9bef9d
Ruark, Elise
c5c08cd3-5579-4525-85b4-a6f2cd5e9a86
Cloke, Victoria
5998e9f4-020a-4409-a8ee-c525ce3ca588
Slade, Ingrid
264e62f4-7c1e-4522-93f2-917de23e31d3
Kemp, Zoe
6d96320b-c976-4ea6-9b87-536deb9bb0c9
Gore, Martin
c38b4500-ccbd-4505-9c58-68c8b27b54f2
Strydom, Ann
e626e499-b5e6-4e23-b128-ddfe844cc97b
Banerjee, Susana
977eaccf-2029-4f7b-8577-4264c04c0550
Hanson, Helen
fe4a8065-8b0d-4b30-a658-cd433570c2ec
Rahman, Nazneen
d5eded76-0af9-4d72-8fea-84986bf49c51

George, Angela, Riddell, Daniel, Seal, Sheila, Talukdar, Sabrina, Mahamdallie, Shazia, Ruark, Elise, Cloke, Victoria, Slade, Ingrid, Kemp, Zoe, Gore, Martin, Strydom, Ann, Banerjee, Susana, Hanson, Helen and Rahman, Nazneen (2016) Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Scientific Reports, 6, 29506. (doi:10.1038/srep29506).

Record type: Article

Abstract

Advances in DNA sequencing have made genetic testing fast and affordable, but limitations of testing processes are impeding realisation of patient benefits. Ovarian cancer exemplifies the potential value of genetic testing and the shortcomings of current pathways to access testing. Approximately 15% of ovarian cancer patients have a germline BRCA1 or BRCA2 mutation which has substantial implications for their personal management and that of their relatives. Unfortunately, in most countries, routine implementation of BRCA testing for ovarian cancer patients has been inconsistent and largely unsuccessful. We developed a rapid, robust, mainstream genetic testing pathway in which testing is undertaken by the trained cancer team with cascade testing to relatives performed by the genetics team. 207 women with ovarian cancer were offered testing through the mainstream pathway. All accepted. 33 (16%) had a BRCA mutation. The result informed management of 79% (121/154) women with active disease. Patient and clinician feedback was very positive. The pathway offers a 4-fold reduction in time and 13-fold reduction in resource requirement compared to the conventional testing pathway. The mainstream genetic testing pathway we present is effective, efficient and patient-centred. It can deliver rapid, robust, large-scale, cost-effective genetic testing of BRCA1 and BRCA2 and may serve as an exemplar for other genes and other diseases.

This record has no associated files available for download.

More information

Published date: 13 July 2016
Keywords: Adult, Aged, Aged, 80 and over, BRCA1 Protein/genetics, BRCA2 Protein/genetics, Cost-Benefit Analysis, Female, Genetic Predisposition to Disease, Genetic Testing/economics, Humans, Middle Aged, Models, Organizational, Mutation, Neoplasms/diagnosis, Patient Satisfaction, Patient-Centered Care/economics, Program Development, Surveys and Questionnaires, Young Adult

Identifiers

Local EPrints ID: 506546
URI: http://eprints.soton.ac.uk/id/eprint/506546
ISSN: 2045-2322
PURE UUID: ca2ac898-7943-41e3-ad60-cad788b4696b
ORCID for Ingrid Slade: ORCID iD orcid.org/0009-0005-4946-8688

Catalogue record

Date deposited: 11 Nov 2025 17:40
Last modified: 15 Nov 2025 03:21

Export record

Altmetrics

Contributors

Author: Angela George
Author: Daniel Riddell
Author: Sheila Seal
Author: Sabrina Talukdar
Author: Shazia Mahamdallie
Author: Elise Ruark
Author: Victoria Cloke
Author: Ingrid Slade ORCID iD
Author: Zoe Kemp
Author: Martin Gore
Author: Ann Strydom
Author: Susana Banerjee
Author: Helen Hanson
Author: Nazneen Rahman

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×